• Citer

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

par Body, Jean-Jacques ;Diel, I J;Lichinitser, M R;Kreuser, E.D.;Dornoff, W.;Gorbunova, V.A.;Budde, M.;Bergström, Bengt;MF 4265 Study Group,
Référence Annals of oncology, 14, 9, page (1399-1405)
Publication Publié, 2003-09

Article révisé par les pairs

• Détails
• Contenu

Titre:	Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
Auteur:	Body, Jean-Jacques; Diel, I J; Lichinitser, M R; Kreuser, E.D.; Dornoff, W.; Gorbunova, V.A.; Budde, M.; Bergström, Bengt; MF 4265 Study Group,
Informations sur la publication:	Annals of oncology, 14, 9, page (1399-1405)
Statut de publication:	Publié, 2003-09
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Antineoplastic Agents -- adverse effects -- therapeutic use
	Bone Neoplasms -- drug therapy -- epidemiology -- physiopathology -- secondary
	Breast Neoplasms -- drug therapy -- pathology
	Diphosphonates -- adverse effects -- therapeutic use
	Female
	Humans
	Incidence
	Injections, Intravenous
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase III
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:pmid/12954579